RESEARCH ARTICLE

Association between serum magnesium levels and abdominal aorta calcification in patients with pre-dialysis chronic kidney disease stage 5

Mayumi Ito¹, Makoto Yamaguchi¹, Takayuki Katsuno¹, Hironobu Nobata¹, Shiho Iwagaitsu¹, Hirokazu Sugiyama¹, Hiroshi Kinashi¹, Shogo Banno¹, Masahiko Ando², Yoko Kubo³, Takuji Ishimoto⁴, Yasuhiro Ito¹*

¹ Department of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan, ² Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan, ³ Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴ Department of Nephrology and Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Nagoya, Japan

* yasuito@aichi-med-u.ac.jp

Abstract

Background

Several studies have revealed the relationship between serum magnesium levels and vascular calcification in chronic kidney disease patients. Despite excellent predictability of abdominal aorta calcification for cardiovascular disease events, the relationship between serum magnesium levels and abdominal aorta calcification, as evaluated by quantitative methods, in pre-dialysis patients remains unclear. This study aimed to determine the abdominal aorta calcification volume using computerized tomography and its association with serum magnesium levels in pre-dialysis chronic kidney disease stage 5 patients.

Methods

This single-center cross-sectional study included 100 consecutive patients with pre-dialysis chronic kidney disease stage 5 between January 2016 and May 2020 at Aichi Medical University Hospital, Japan. The relationships between serum magnesium levels and the abdominal aorta calcification volume were assessed using multiple linear regression models after adjusting for clinically relevant factors. We also assessed clinical factors that affect serum magnesium levels.

Results

The mean serum magnesium level was 2.0 mg/dL (interquartile range, 1.8 to 2.3). Multivariate analyses revealed that a higher serum magnesium level (stand. β = -0.245, p = 0.010) was significantly associated with a reduced abdominal aorta calcification volume, and that a history of cardiovascular disease (stand. β = 0.3792, p < 0.001) and older age (stand. β = 0.278, p = 0.007) were significantly associated with an increased abdominal aorta calcification volume.
calcification volume. Moreover, multivariate analysis showed that the use of proton pump inhibitor or potassium-competitive acid blocker was significantly associated with lower serum magnesium levels (stand. \( \beta = -0.246, p = 0.019 \)).

**Conclusions**
The present study revealed that the higher Mg level was significantly associated with lower volume of abdominal aorta calcification in pre-dialysis chronic kidney disease stage 5 patients. Further studies should be undertaken to determine the appropriate magnesium level to suppress vascular calcification.

**Introduction**
Cardiovascular disease (CVD) is the most common cause of mortality in patients with chronic kidney disease (CKD) [1]. Although vascular calcification (VC) is considered an important risk factor for CVD [2], no specific therapy is available to prevent progression or to facilitate regression of VC; therefore, it is essential to identify clinical factors leading to VC and establish a preventive strategy for VC.

A large number of factors are responsible for development of VC in CKD, especially in mineral disorders [3], and phosphate (P) and calcium (Ca) are major contributors to development of medial calcification. In addition, several observational studies have shown that serum magnesium (Mg) levels inversely correlate with VC only in dialysis patients [4–7], and some experimental studies have demonstrated the importance of Mg as an anti-calcification mineral [8–15]. However, the serum Mg level is largely dependent on the dialysate Mg level [16]. Therefore, the findings of these observational studies that assessed dialysis patients should be interpreted cautiously; moreover, it remains unclear whether there is a similar relationship in pre-dialysis settings. Furthermore, methods for detection and quantification of VC, as well as baseline Mg levels, are different in various studies [7–15]. Thus, the relationship between the serum Mg level and VC remains to be investigated.

Accumulating evidence indicates that abdominal aorta calcification (AAC) is a good clinical target to evaluate atherosclerosis in the abdominal aorta and is a marker of subclinical atherosclerotic disease [17–24], and it correlates with asymptomatic coronary artery disease [17] and is highly predictive of subsequent VC outcomes in the general population [18, 19]. In CKD patients under hemodialysis and peritoneal dialysis, AAC could be used to predict CVD outcomes and total mortality [24]. AAC can be measured with methods, such as X-ray [25] or computerized tomography (CT) [26]. Compared with plain X-ray, CT can easily quantify AAC with objective and reproducible results [27, 28]; however, no studies have assessed the relationship between serum Mg levels and AAC evaluated using CT. Therefore, in the present study, we assessed the relationship between serum Mg levels and AAC using quantitative methods of VC with CT in patients with pre-dialysis CKD stage 5.

**Materials and methods**

**Ethical statements**
The study protocol was approved by the Ethics Committee of Aichi Medical University (approval number: 2018-H350; date: November 3, 2019). Due to the retrospective nature of the study, the need for patients’ informed consent was waived.
Participants
The study included patients who were hospitalized for chronic hemodialysis between January 2016 and May 2020 at Aichi Medical University Hospital, Nagakute Aichi, Japan. Of the total 146 patients for whom hemodialysis was newly started, we included those who underwent at least two blood examinations of serum Ca, P, and Mg levels as well as abdominal CT scans that were used to screen for malignancy and vascular disease (aortic aneurysms, pleural effusion) by physician’s practice within 3 months prior to first hemodialysis. Finally, after excluding 34 patients with missing Mg data and 12 patients without abdominal CT scans, a total of 100 (68.5%) patients were included in the present study (Fig 1).

Measurements
The following clinical data were obtained from medical records at the time of the first blood examination as baseline characteristics: age, sex, body mass index (BMI), and systolic/diastolic blood pressure (SBP/DBP); prescription of phosphate binders (calcium carbonate, lanthanum carbonate, sucroferric oxyhydroxide, and ferric citrate hydrate), proton pump inhibitors (PPI), potassium-competitive acid blocker (P-CAB), histamine-2 receptor blocker, statin, diuretic, antplatelet drugs, vitamin K antagonist, antihypertensive medication, magnesium oxide (MgO), insulin, erythropoetine, and oral intravenous active vitamin D analog; and history of CVD (myocardial infarction, cerebral infarction, cerebral hemorrhage, and amputation of the extremities), diabetes mellitus (DM), hypercholesterolemia, hypertension (HT), and ever smoking. DM was defined as 1) a fasting serum glucose level of ≥ 126 mg/dL, 2) a random serum glucose level of ≥ 200 mg/dL, 3) a hemoglobin A1c level of ≥ 6.5%, and/or 4) prescription of glucose-lowering drugs, including insulin. Hypercholesterolemia was defined as a total serum cholesterol level of 240 mg/dL or the use of lipid-lowering medications. Hypertension was defined as taking antihypertensive medications or a systolic blood pressure (BP) of ≥ 140 mmHg and/or a diastolic BP of ≥ 90 mmHg. Smokers were defined as both current smokers and ex-smokers.

![Flow diagram of patient selection](https://doi.org/10.1371/journal.pone.0253592.g001)
Laboratory measurements (serum levels of albumin, Ca, P, Mg, creatinine, estimate glomerular filtration rate (eGFR), total cholesterol, high and low-density lipoprotein (HDL and LDL) cholesterol, triglyceride (TG), hemoglobin, C-reactive protein (CRP), alkaline phosphatase, and intact parathyroid hormone [iPTH]) were averaged using the laboratory values collected during the three months prior to the first dialysis. If the serum albumin level was < 4.0 g/dL, the serum Ca level was adjusted as follows: corrected serum Ca level (mg/dL) = measured serum Ca level (mg/dL) + (4.0—serum albumin level (g/dL).

Evaluation of abdominal aorta calcification

AAC volume was evaluated using CT scans. Abdominal images were obtained using multidetector CT scanners at the Aich Medical University of Nagakute, Aichi (SOMATOM Definition AS+ 128 slices, 64-row [Siemens] and SOMATOM Definition Flash [Siemens]). Images were reconstructed with a slice thickness of 2 mm (multi-detector scanners). For equal comparisons among participants with different abdominal aortic lengths, an 8 cm segment proximal to the aortic bifurcation was used to quantify AAC with the method of Forbang NI et al. [29].

The volume of AAC (cm$^3$) was quantified using the definition of calcification in the Agatston score [17]. CT values of Hounsfield Units greater than 130 in each slice were defined as dominant calcification, and calcification of the abdominal aortic wall was identified in each slice of 2.5 mm thickness; they were automatically calculated by image processing software (Ziostation2, Ziosoft, Inc.).

Statistical analyses

We stratified patients into the following 3 categories according to the tertile of serum Mg levels: lower (< 1.9 mg/dL), intermediate (1.9–2.2 mg/dL), and higher (≥ 2.2 mg/dL). Clinical characteristics were compared using the Kruskal–Wallis test followed by Mann–Whitney post-hoc analysis with Bonferroni correction or Pearson’s chi-square test, when appropriate. To determine the factors that were independently associated with VC, we evaluated the AAC volume using univariate linear regression analysis. Multiple linear regression analysis for the AAC volume was performed with adjustment for the following clinically relevant factors: age; sex; SBP; serum adj. Ca, Mg, P, and iPTH level; and history of CVD, DM, and HT. Correlations between continuous data were assessed using Pearson’s or Spearman’s test, as appropriate. Furthermore, to determine the clinical factors associated with the serum Mg level, multiple linear regression analysis was performed with adjustment for the following clinically relevant factors: age; sex; serum albumin and iPTH level; prescription of phosphate binders and MgO; and history of CVD and DM. The level of statistical significance was set at $P < 0.05$. All analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC) and SPSS statistics version 26 (Stata Corp, College Station, USA).

Results

Baseline characteristics

Baseline characteristics of patients according to the tertiles of serum Mg levels are outlined in Table 1. Among all patients, 31% were in the lower Mg group (< 1.9 mg/dL), 38% were in the intermediate Mg group (1.9–2.2 mg/dL), and 31% were in the higher Mg group (≥ 2.2 mg/dL). Patients in the higher Mg group showed higher adjusted serum Ca level ($p = 0.023$), lower AAC volume ($p < 0.001$), lower prevalence of PPI/P-CAB use ($p = 0.020$), and higher prevalence of...
Table 1. Baseline characteristics of patients stratified by Mg categories.

| Characteristics                      | Magnesium groups (range of serum magnesium levels [mg/dL]) | P values |
|--------------------------------------|-----------------------------------------------------------|----------|
|                                      | Total n = 100    | lower (< 1.9) n = 31 | intermediate (≥ 1.9, < 2.2) n = 38 | higher (≥ 2.2) n = 31 |
| Age, year                            | 72 [63, 79]      | 73 [64, 80]           | 75 [64, 81]                           | 71 [55, 76]          | .352     |
| Male, n (%)                          | 69 (69)         | 21 (67)               | 24 (63)                               | 24 (77)             | .437     |
| BMI, kg/m²                           | 21 [19, 24]     | 22 [15, 27]           | 20 [13, 27]                           | 21 [14, 34]         | .444     |
| History of CVD, n (%)                | 28 (28.0)       | 8 (25.8)              | 21 (55.3)                             | 7 (22.6)            | .535     |
| smoker, n (%)                        | 55 (55.0)       | 17 (54.8)             | 21 (55.3)                             | 17 (56.7)           | .989     |
| DM, n (%)                            | 59 (59.0)       | 21 (67.7)             | 20 (52.6)                             | 18 (58.1)           | .444     |
| Duration of DM, year                 | 9 [0, 21]       | 8 [0, 23.5]           | 0 [0, 20.75]                          | 18 [0, 20]          | .434     |
| HT, n (%)                            | 95 (95.0)       | 31 (100.0)            | 35 (92.1)                             | 29 (93.5)           | .295     |
| Hypercholesterolemia, n (%)          | 38 (38.8)       | 12 (40.0)             | 11 (29.7)                             | 15 (48.4)           | .286     |
| SBP, mmHg                            | 150 [131, 164]  | 146 [132, 162]        | 154 [132, 165]                        | 150 [134, 162]      | .977     |
| DBP, mmHg                            | 75 [65, 84]     | 75 [64, 83]           | 76 [64, 83]                           | 74 [69, 84]         | .969     |
| eGFR, mL/min/1.73m²                  | 5 [4.6, 7]      | 6 [4, 7]              | 5 [5, 6.8]                            | 6 [4, 7.5]          | .746     |
| P, mg/dL                             | 5.4 [4.5, 6.7]  | 5.7 [4, 7.6]          | 5.5 [4.8, 6.6]                        | 5.1 [4.5, 6.3]      | .661     |
| Adj. Ca, mg/dL                       | 9.0 [8.6, 9.3]  | 8.8 [8.5, 9.1]        | 9.1 [8.9, 9.3]                        | 9.0 [8.5, 9.3]      | .023     |
| Ca×P                                 | 49.5 [43.4, 62.5] | 49.5 [44.1, 62.6] | 50.9 [43.7, 61.7] | 48.0 [41.4, 56.1] | .437     |
| CRP, mg/dL                           | 0.41 [0.16, 2.01] | 0.32 [0.14, 2.39]     | 0.44 [0.18, 2.02] | 0.30 [0.10, 0.85] | .666     |
| Hb, g/dL                             | 9.9 [8.8, 10.9] | 9.6 [8.8, 10.4]       | 10.3 [8.8, 11.2]                      | 9.8 [8.7, 10.7]     | .439     |
| Alb, g/dL                            | 3.1 [2.7, 3.5]  | 3.1 [2.7, 3.5]        | 3.1 [2.6, 3.5]                        | 3.1 [2.8, 3.6]      | .652     |
| ALP, IU                              | 234 [179, 301]  | 223 [187, 280]        | 245 [181, 332]                        | 233 [177, 296]      | .800     |
| iPTH, pg/mL                          | 251 [154, 381]  | 238 [189, 369]        | 213 [126, 351]                        | 264 [192, 387]      | .634     |
| TC, mg/dL                            | 171 [146, 199]  | 161 [136, 180]        | 171 [141, 206]                        | 176 [165, 198]      | .231     |
| HDL-C, mg/dL                         | 45 [35.5, 57]   | 48 [38.5, 66]         | 46 [35, 51]                           | 43 [36.5, 54.5]     | .299     |
| Hyper-LDL-cholesterolemia (LDL-C ≥140 mg/dL), n (%) | 11 (12.0) | 3 (10.7) | 4 (11.1) | 4 (14.3) | .900     |
| TG, mg/dL                            | 113 [84, 153]   | 118 [83, 147]         | 102 [79, 143]                         | 113 [98, 157]       | .488     |
| Cr, mg/dL                            | 7.54 [6.23, 9.73] | 8.10 [7.03, 9.83]     | 7.15 [5.92, 8.15]                     | 7.88 [6.19, 10.51]  | .288     |
| Fe, μg/dL                            | 51 [36, 69]     | 51 [36, 54]           | 52 [39, 71]                           | 55 [36, 69]         | .509     |
| UPCR, g/gCr                           | 4.77 [2.17, 7.45] | 6.33 [3.52, 8.99]     | 3.96 [2.48, 7.02]                     | 4.16 [1.83, 6.08]   | .076     |

Prescription

| Phosphate binder                      | 36 (36.0) | 10 (32.3) | 15 (39.5) | 11 (35.5) | .822     |
| Calcium carbonate, n (%)              | 19 (19)   | 7 (22.6)  | 3 (7.9)   | 9 (29.0)  | 0.07     |
| Lanthanum, n (%)                      | 15 (15)   | 5 (16.1)  | 4 (7.9)   | 7 (22.6)  | .231     |
| Sucroferric oxyhydroxide, n (%)       | 1 (1)     | 0 (0)     | 0 (0)     | 1 (3.2)   | .325     |
| Ferric Citrate Hydrate, n (%)         | 9 (9)     | 4 (12.9)  | 5 (13.2)  | 0 (0)     | .108     |
| Duration of Phosphate binder (month)  | 3 [2, 5.5] | 4 [2, 6]  | 2 [2, 5.5] | 4 [2, 4.5] | .781     |
| MgO, n (%)                            | 3 (3)     | 0 (0)     | 0 (0)     | 3 (9.7)   | .032     |
| Duration of MgO, (month)              | 2 [2, 10] | 0 (0)     | 0 (0)     | 2 [2, 10] | .033     |
| PPI/P-CAB, n (%)                      | 31(31)    | 14 (45.2) | 13 (34.2) | 4(12.9)   | .020     |
| Duration of PPI/P-CAB, (year)         | 2 [1, 4]  | 3 [2, 5]  | 2 [1, 3.5] | 2 [1.5]   | .554     |
| Vitamin D therapy (p.o.), n (%)       | 37 (37)   | 13 (41.9) | 14 (36.8) | 10 (32.3) | .732     |
| H2 blocker, n (%)                     | 1(1)      | 0 (0)     | 1 (2.6)   | 0 (0)     | .439     |
| Warfarin, n (%)                       | 8(8)      | 1 (4)     | 4 (12.5)  | 3 (10.3)  | .533     |
| Anti-platelet drug, n (%)             | 16(16)    | 7 (22.6)  | 7 (18.4)  | 2 (6.5)   | .195     |
| Diuretic, n (%)                       | 70(70)    | 21 (67.7) | 30 (78.9) | 19 (61.3) | .267     |
| Statin, n(%)                          | 32(32)    | 14 (45.2) | 9 (23.7)  | 9 (31.0)  | .163     |

(Continued)
MgO use (p = 0.032) than those in the lower Mg group. Other findings were comparable among the three groups.

Clinical factors affecting the AAC volume

In the univariate analysis, older age, higher serum adjusted Ca levels, and a history of CVD were significantly associated with an increased AAC volume, and higher serum Mg levels and the use of MgO were significantly associated with a reduced AAC volume (p < 0.005) (Table 2). Multiple linear regression analysis revealed that a history of CVD (stand. β = 0.379, p < 0.001) and older age (stand. β = 0.278, p = 0.007) were significantly associated with an increased AAC volume, and higher Mg levels (stand. β = -0.245, p = 0.010) were significantly associated with a reduced AAC volume (Table 3). As well as in the relative AAC volume by BSA adjustment, these results had not been changed significantly (S1 Table).

Clinical factors affecting serum Mg levels

Univariate analysis showed that the use of PPI/P-CAB was associated with lower Mg levels, and the use of MgO was associated with higher Mg levels (p < 0.005) (S1 Table). Multivariate analysis showed that the use of PPI/P-CAB (β = -0.246, p = 0.019) was associated with lower serum Mg levels, and the use of MgO was associated with higher serum Mg levels (β = 0.295, p = 0.005) (Table 4).

Discussion

The present study revealed that higher Mg levels were significantly associated with lower volume of abdominal aorta calcification in pre-dialysis chronic kidney disease stage 5 patients. This finding suggests that the higher serum Mg level might suppress VC in the abdominal aorta. To the best of our knowledge, this study is the first to evaluate the relationship between the serum Mg level and AAC calculated by quantitative methods with CT in pre-dialysis CKD stage 5 patients. Previous studies have demonstrated that serum Mg levels inversely correlate with VC in dialysis patients [4–7]. For example, one study including 52 hemodialysis patients with VC and 338 without VC found that serum Mg levels were independently associated with VC after adjusting for age, sex, hemodialysis vintage, Ca, P, and PTH concentration (odds ratio = 0.28, 

| Table 1. (Continued) |
|----------------------|------------------|------------------|
| Characteristics      | Magnesium groups (range of serum magnesium levels [mg/dL]) | P values |
| Total n = 100        | lower (< 1.9) | intermediate (≥ 1.9, < 2.2) | higher (≥ 2.2) |
| ESA, n (%)           | n = 31         | n = 38            | n = 31         |
| 75 (75)              | 21 (67.7)      | 29 (76.3)         | 25 (80.6)      |
| Volume of AAC, cm³   | 3.25 [1.62, 7.10] | 4.43 [2.98, 7.46] | 3.80 [2.01, 8.58] |
| Relative Volume of AAC, (cm³/m² BSA) | 2.24 [0.96, 4.60] | 3.55 [1.86, 4.78] | 2.59 [1.26, 5.60] |

| Data are presented as number (percent) or median [interquartile range]. |
| Abbreviations: BMI, body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; HT, hypertension; SBP, Systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimate glomerular filtration rate; P, phosphate; adj.Ca, adjusted calcium; CRP, C-reactive protein; Hb, hemoglobin; Alb, albumin; ALP, alkaline phosphatase; iPTH, intact parathyroid hormone; TC, total cholesterol; HDL, high density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; Cr, creatinine; Fe, ferritin; UPCR, urine protein to creatinine ratio; MgO, magnesium oxide; PPI, proton pump inhibitor; P-CAB, potassium-competitive acid blocker; H₂, histamine-2 receptor; ESA, erythropoiesis stimulating agents; AAC, abdominal aortic calcification; BSA, body surface area. |

https://doi.org/10.1371/journal.pone.0253592.t001

*25OH vitamin D, alfacalcidol or eldecalcitol.
95% CI = 0.09–0.92) [5]; however, that study focused on only non-DM patients, other arteries (except for hand arteries) were not evaluated for VC, and the methods for calculating VC were not quantitative. In addition, another study, including 80 peritoneal dialysis patients with DM or non-DM, evaluated VC using XP in the abdominal aorta and found that a higher serum Mg level was associated with decreased AAC after adjusting for age, serum P, PTH, LDL-C, smoking history, and diabetes [6]; the serum Mg level was 0.84 mmol/L, which is almost the same as that in our cohort but is lower than that in the hemodialysis population [30–33]. The results of serum Mg concentration in that study [6] might be significantly influenced by low Mg-contained peritoneal dialysate solution.

### Table 2. Univariate linear regression for AAC volume.

| Variable          | stand. B | SE  | T       | P values |
|-------------------|----------|-----|---------|----------|
| Age               | .354     | .028| 3.759   | <.001    |
| Male              | -.075    | .862| -.743   | .459     |
| BMI               | -.081    | .094| -.803   | .424     |
| History of CVD    | .392     | .819| 4.221   | <.001    |
| Smoker            | .038     | .810| .379    | .705     |
| DM                | .103     | .808| 1.025   | .308     |
| Duration of DM    | .152     | .030| 1.527   | .130     |
| HT                | .188     | 1.801| 1.899   | .061     |
| Hypercholesterolemia| .109   | .830| 1.074   | .286     |
| SBP, mmHg         | -.076    | .014| -.755   | .452     |
| P                 | -.081    | .272| -.807   | .422     |
| Adj. Ca           | .213     | .524| 2.155   | .034     |
| Ca×P              | -.002    | .026| -.023   | .982     |
| iPTH              | -.001    | .001| -.645   | .521     |
| Magnesium         | -.254    | .958| -2.600  | .011     |
| Albumin           | .029     | .682| .290    | .773     |
| TC                | .099     | .010| .973    | .333     |
| HDL-C             | .012     | .026| .112    | .911     |
| LDL-C             | .084     | .012| .796    | .428     |
| TG                | .122     | .004| 1.177   | .242     |
| CRP               | -.109    | .139| -1.081  | .282     |
| Prescription      |          |     |         |          |
| Phosphate binder  | .055     | .831| .548    | .585     |
| Duration of Phosphate binder | -.163 | .087| -.952   | .348     |
| PPI/P-CAB         | .028     | .313| .548    | .585     |
| Duration of PPI/P-CAB | .025 | .276| .244    | .807     |
| MgO               | -.720    | 1.437| 2.236   | .028     |
| Duration of MgO   | -.876    | .190| -1.820  | .320     |
| H₂ blocker        | .060     | .849| .273    | .785     |
| Warfarin          | .220     | 4.009| .593    | .555     |
| Statin            | .338     | 2.341| .308    | .759     |
| Insulin           | -.110    | .993| -1.091  | .278     |
| ESA               | .024     | .923| .239    | .812     |

Abbreviations: stand. β, standardized β-coefficient; SE, standard error of stand. β; BMI, body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; HT, hypertension; SBP, Systolic blood pressure; eGFR, estimate glomerular filtration rate; P, phosphate; adj.Ca, adjusted calcium; TC, total cholesterol; HDL, high density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; iPTH, intact parathyroid hormone; CRP, C-reactive protein; P-CAB, potassium-competitive acid blocker; H₂, histamine-2 receptor; MgO, magnesium oxide; PPI, proton pump inhibitor; AAC, abdominal aortic calcification; ESA, erythropoiesis stimulating agents.

https://doi.org/10.1371/journal.pone.0253592.t002
With regard to clinical factors other than Mg associated with AAC, studies have shown that high levels of serum P, Ca, and iPTH are risk factors for VC [34]. IPTH can increase the expression of the cartilage matrix and enhance the intracellular Ca levels, thereby promoting the formation of VC [35, 36]. Furthermore, a recent RCT reported that strict phosphate control delays the progression of coronary artery calcification in a dialysis population [37]. However, our study showed that serum levels of Ca, P, and iPTH were not associated with AAC. There are several possible reasons for this, such as study design, time of testing, and number of times tested. We postulate that this difference is probably because the serum P, Ca, and iPTH levels in most of our patients were within the target range and our small sample size, leading to a low statistical power which is unable to estimate the association between P, Ca, and iPTH with AAC. Additionally, serum P level might be influenced by a patient’s nutritional state, but the amount of phosphate in the diet could not be evaluated in our study. For example, in patients who had had appetite loss due to uremia, phosphate level at the time of starting dialysis might be lower, resulting in a possible underestimation of the influence of serum P levels on AAC. Therefore, more well-designed RCTs should be undertaken in order to clarify

Table 3. Multiple linear regression for AAC volume.

| Variable        | stand. β | SE    | T      | P value |
|-----------------|----------|-------|--------|---------|
| Age             | .278     | .029  | 2.747  | .007    |
| Male            | -.050    | .893  | -1.472 | .151    |
| History of CVD  | .379     | .857  | 3.941  | <.001   |
| DM              | .154     | .754  | 1.609  | .112    |
| HT              | .093     | 1.714 | .513   | .614    |
| SBP             | -.045    | .015  | -2.45  | .016    |
| P               | .090     | .257  | .389   | .372    |
| adj. Ca         | .062     | .556  | .584   | .561    |
| iPTH            | -.103    | .001  | -3.118 | <.001   |
| Magnesium       | -.245    | .877  | -2.658 | .010    |

Abbreviations: stand. β, standardized β-coefficient; SE, standard error of stand. β; CVD, cardiovascular disease; DM, diabetes mellitus; HT, hypertension; SBP, Systolic blood pressure; P, phosphate; adj.Ca, adjusted calcium; iPTH, intact parathyroid hormone; AAC, abdominal aortic calcification.

https://doi.org/10.1371/journal.pone.0253592.t003

Table 4. Multiple linear regression for serum Mg levels.

| Variable       | stand. β | SE    | T      | P value |
|----------------|----------|-------|--------|---------|
| Age            | .032     | .003  | .306   | .760    |
| Male           | .133     | .097  | 1.218  | .227    |
| History of CVD | .037     | .098  | .356   | .723    |
| DM             | -.071    | .084  | -.692  | .491    |
| Albumin        | .003     | .071  | .031   | .975    |
| iPTH           | -.059    | <.001 | -.561  | .576    |
| Prescription   |          |       |        |         |
| PPI/P-CAB      | -.246    | .096  | -2.387 | .019    |
| MgO            | .295     | .233  | 2.870  | .005    |

Abbreviations: stand. β, standardized β-coefficient; SE, standard error of stand. β; BMI, body mass index; CVD, cardiovascular disease; DM, diabetes mellitus; iPTH, intact parathyroid hormone; PPI, proton pump inhibitor; P-CAB, potassium-competitive acid blocker; MgO, magnesium oxide.

https://doi.org/10.1371/journal.pone.0253592.t004
whether strict phosphate control delays progression of AAC in pre-dialysis CKD patients. Furthermore, as for the phosphate level control, although phosphate binders have been demonstrated to improve mineral metabolism and reduce cardiovascular mortality and morbidity in end-stage chronic kidney disease [38], in this study, phosphate binders were not associated with AAC and serum Mg levels. This may be due to the retrospective nature of the present study; the types and amount of phosphate binders were not standardized but rather left to each physician’s discretion; and the short duration of prescription and therefore had a clinically small impact on anti-vascular calcification. Therefore, in our study, the effect of phosphate binders on phosphate and Mg levels could not be precisely evaluated. In order to clarify the possible effect of phosphate binders on AAC, a well-designed RCT should be performed in the future.

Regarding other factors that may be responsible for development of VC, decreased eGFR levels have been reported to be related to an increased AAC [39]; however, our results did not show any significant association between eGFR level and AAC. This is possibly due to the fact that our study only included patients with CKD stage 5, just before starting dialysis with eGFR levels within a narrow range, thus, we postulate that these small differences in eGFR levels have a negligible influence on AAC. Further studies including patients with various eGFR level should be undertaken in order to reveal the relationship between eGFR level and AAC in the future.

In addition, some previous reports showed that erythropoietin (EPO) and hypoxia-inducible factor (HIF) have been associated with vascular calcification. One study reported that EPO attenuates vascular calcification by inhibiting endoplasmic reticulum stress in rats with CKD [40]; meanwhile, other studies have reported that EPO and HIF-1 can promote vascular calcification in CKD, suggesting that inappropriate use of EPO and prolyl HIF-hydroxylase (PH) enzyme (HIF-PH) inhibitors in CKD patients might aggravate vascular calcification and elicit adverse clinical consequences [41, 42]. In this study, no significant association between use of ESA and AAC was found. However, in order to clarify the influence of ESA and HIF-PH for anti-vascular calcification, large scale, well designed RCTs should be undertaken in the future.

As for clinical factors that affect serum Mg levels, studies have shown that some medications may affect serum Mg levels in CKD patients. Consistently, the present study revealed that the use of PPI/P-CAB was a risk factor for lower serum Mg levels, probably because anti-gastric acid medication hampers intestinal Mg reabsorption and consequently increases the risk of hypomagnesemia [43, 44].

A number of experimental studies have suggested that administration of Mg prevents VC [45–47], and the potential mechanisms include the inhibition of calcium-phosphate crystal growth in the circulation, thus decreasing calcium-phosphate deposition, and prevention of the phenotype change of the vascular smooth muscle to osteoblasts [45, 46]. However, no large-scale clinical studies have elucidated the clinical efficacy of Mg supplements in CKD. Therefore, well-designed randomized controlled trials are needed to illustrate the preventive effects of Mg on VC in CKD patients.

There are some limitations to this study. First, the study was a cross-sectional study and had a small sample size; therefore, the causal relationship between Mg and VC could not be fully determined, and there might be other confounding factors that could not be adjusted. Second, we could not obtain precise information regarding changes in dosage and serum levels for MgO, PPI/P-CAB, and phosphate binders over the study period, and the prescription methods were not standardized. Furthermore, we only assessed the relationship between Mg levels and AAC just before starting dialysis; therefore, it is difficult to conclude that there is a close relationship between Mg levels just before dialysis and AAC. Further studies should obtain the data about these drug prescriptions and Mg levels over the entire period of ongoing
vascular calcification. Third, we did not evaluate the AAC progression and CVD prognosis; therefore, well-designed longitudinal studies should be undertaken to assess these points in the future.

Fourth, we did not assess the difference between medial and intimal calcification, although intimal calcification has been demonstrated to be associated with worse survival compared with medial calcification [47, 48]. Therefore, further studies are needed to address these limitations.

In conclusion, this cohort study found that higher Mg levels were associated with lower volume of AAC in pre-dialysis chronic kidney disease stage 5 patients. Further studies should be undertaken to identify the appropriate Mg level for suppressing VC in CKD patients.

Supporting information
S1 Table. Multiple linear regression for relative AAC volume (cm$^3$/m$^2$ BSA).
(DOCX)
S2 Table. Univariate linear regression for serum Mg levels.
(DOCX)

Acknowledgments
The authors are grateful to all the medical staff who participated in this study.

Author Contributions
Conceptualization: Mayumi Ito.
Data curation: Mayumi Ito.
Formal analysis: Mayumi Ito, Masahiko Ando, Yoko Kubo.
Methodology: Mayumi Ito.
Project administration: Makoto Yamaguchi.
Supervision: Makoto Yamaguchi, Takayuki Katsuno, Hironobu Nobata, Shiho Iwagaitu, Hironobu Hitokazu Sugiyama, Hiroshi Kinashi, Shogo Banno, Masahiko Ando, Takuji Ishimoto, Yasuhiro Ito.
Writing – original draft: Mayumi Ito, Makoto Yamaguchi.
Writing – review & editing: Makoto Yamaguchi.

References
1. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998; 11:239–245. PMID: 9831236
2. Leow K, Szulc P, Schousboe JT, Kiel DP, Teixeira-Pinto A, Shaikh H, et al. Prognostic value of abdominal aortic calcification: A systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2021; 10:e017205. https://doi.org/10.1161/JAHA.120.017205 PMID: 33439672
3. Shanahan CM, Crouthamel MH, Kapustín A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate Circ Res. 2011; 109(6):697–711. https://doi.org/10.1161/CIRCRESAHA.110.234914 PMID: 21885837
4. Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2017; 91(4):808–817. https://doi.org/10.1016/j.kint.2016.09.024 PMID: 27914706
5. Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol. 2007; 68(4):222–227. https://doi.org/10.5414/cnp66222 PMID: 17969489
24. Louvet L, Bazin D, Buchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Characterisation of calcium muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. PLoS One. 2017; 18(1):129. https://doi.org/10.1161/01.cir.103.11.1529 PMID: 11257080

7. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension. 2010; 56:453–462. https://doi.org/10.1161/HYPERTENSIONAHA.110.152058 PMID: 20696983

8. Sakaguchi Y, Hamano T, Nakano C, Obi Y, Matsu I, Kusunoki Y, et al. Association between density of coronary artery calcification and serum magnesium levels among patients with chronic kidney disease. PLoS One. 2016; 11(9):e0163673. https://doi.org/10.1371/journal.pone.0163673 PMID: 27662624

9. Kirceli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, Steppan S, et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant. 2012; 27:514–521. https://doi.org/10.1093/ndt/gfr321 PMID: 21750166

10. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol. 2012; 35:31–39. https://doi.org/10.1159/000334742 PMID: 22179063

11. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant. 2013; 28:869–878. https://doi.org/10.1093/ndt/gfs520 PMID: 23229924

12. Montes de Oca A, Guerrero F, Martinez-Moreno JM, Madueño JA, Herencia C, Peralta A, et al. Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One. 2014; 9:e89525. https://doi.org/10.1371/journal.pone.0089525 PMID: 24586847

13. Louvet L, Bazin D, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Characterisation of calcium phosphate crystals on calcified human aortic smooth muscle cells and potential role of magnesium. PLoS One. 2015; 10:e015342. https://doi.org/10.1371/journal.pone.015342 PMID: 25607936

14. Xu J, Bai Y, Jin J, Zhang J, Zhang S, Cui L, et al. Magnesium modulates the expression levels of calcification-associated factors to inhibit calcification in a time-dependent manner. Exp Ther Med. 2015; 9:1028–1039. https://doi.org/10.3892/etm.2015.2215 PMID: 25667672

15. Bai Y, Zhang J, Xu J, Cui L, Zhang H, Zhang S, et al. Magnesium prevents β-glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells. Biomed Rep. 2015; 3:593–597. https://doi.org/10.3892/br.2015.473 PMID: 26171172

16. Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin Kidney J. 2012; 5:i39–i51 https://doi.org/10.1093/ndtplus/sfr166 PMID: 26069820

17. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15:827–832. https://doi.org/10.1016/0735-1097(90)90282-4 PMID: 2407762

18. Alexopoulos N, Raggi P. Calcification in atherosclerosis. Nat Rev Cardiol. 2009; 6:681–688. https://doi.org/10.1038/nrcardio.2009.165 PMID: 19786983

19. Otto CM, Burwash IG, Leggett ME, Munt BI, Fujioka M, Healy NL, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997; 95:2262–2270. https://doi.org/10.1161/01.cir.95.9.2262 PMID: 9142003

20. de Weert TT, Cakir H, Rozie S, Cretier S, Meijering E, Dippel DW, et al. Intracranial internal carotid artery calcifications: association with vascular risk factors and ischemic cerebrovascular disease. AJNR Am J Neuroradiol. 2009; 30:177–184. https://doi.org/10.3174/ajnr.A1301 PMID: 18842764

21. Budoff MJ, Nasir K, Katz R, Takasu J, Carr JJ, Wong ND, et al. Thoracic aortic calcification and coronary heart disease events: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2011; 215:196–202. https://doi.org/10.1016/j.atherosclerosis.2010.11.017 PMID: 21227418

22. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014; 83:E212–220. https://doi.org/10.1002/ccd.25387 PMID: 24402839

23. An C, Lee HJ, Lee HS, Ahn SS, Choi BW, Kim MJ, et al. CT-based abdominal aortic calcification score as a surrogate marker for predicting the presence of asymptomatic coronary artery disease. Eur Radiol. 2014; 24:2491–2498. https://doi.org/10.1007/s00330-014-3298-3 PMID: 25030461

24. Wilson PW, Kauppila LI, O’Donnell CJ, Kiel DP, Hannan M, Polak JM, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation. 2001; 103:1529–1534. https://doi.org/10.1161/01.cir.103.11.1529 PMID: 11257080
25. Kauppila LJ, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997; 132:245–250. https://doi.org/10.1016/s0021-9150(97)00106-8 PMID: 9242971

26. Golledge J. Abdominal aortic calcification: clinical significance, mechanisms and therapies. Curr Pharm Des. 2014; 20:5834–5838. https://doi.org/10.2174/1381612820666140212195309 PMID: 24533938

27. NasrAllah MM, Nassaf A, Elshaboni TH, Morise F, Osman NA, Sharaf El Din UA. Comparing different calcification scores to detect outcomes in chronic kidney disease patients with vascular calcification. Int J Cardiol. 2016; 220:884–889. https://doi.org/10.1016/j.ijcard.2016.06.064 PMID: 27400189

28. Mori S, Takaya T, Kinugasa M, Ito T, Takamine S, Fujiwara S, et al. Three-dimensional quantification and visualization of aortic calcification by multidetector-row computed tomography: a simple approach using a volume-rendering method. Atherosclerosis. 2015; 239:622–628. https://doi.org/10.1016/j.atherosclerosis.2014.12.041 PMID: 25554696

29. Forbang NI, McClelland RL, Remigio-Baker RA, Allison MA, Sandfort V, Michos ED, et al. Associations of cardiovascular disease risk factors with abdominal aortic calcium volume and density: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2016; 255:54–58. https://doi.org/10.1016/j.atherosclerosis.2016.10.036 PMID: 27816809

30. Li L, Streja E, Rhee CM, Mehrotra R, Soohoo M, Brunelli SM, et al. Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis. 2015; 66:1047–1055. https://doi.org/10.1053/j.ajkd.2015.05.024 PMID: 26184377

31. Fein P, Weiss S, Ramos F, Singh P, Chattopadhyay J, Avram MM. Serum magnesium concentration is a significant predictor of mortality in peritoneal dialysis patients. Adv Perit Dial. 2014; 30:90–93. PMID: 25338428

32. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res. 2007; 20:237–244. PMID: 18271493

33. Lacson E Jr, Wang W, Ma L, Passlick-Deetjen J. Serum magnesium and mortality in hemodialysis patients in the United States: A Cohort Study. Am J Kidney Dis. 2015; 66:1056–66. https://doi.org/10.1053/j.ajkd.2015.06.014 PMID: 26190226

34. Dsthabantchong S. Phosphate and Cardiovascular Disease beyond Chronic Kidney Disease and Vascular Calcification. Int J Nephrol. 2018;3162806. https://doi.org/10.1155/2018/3162806 PMID: 29850246

35. Nitta K, Ogawa T. Vascular calcification in end-stage renal disease patients. Contrib Nephrol. 2015; 185:156–167. https://doi.org/10.1159/000380980 PMID: 26023025

36. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004; 15:2857–67. https://doi.org/10.1097/01.ASN.0000141960.01035.28 PMID: 15504939

37. Isaka Y, Hamano T, Fuji H, Tsujimoto Y, Koiwa F, Sakaguchi Y, et al. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. J Am Soc Nephrol. 2021 Mar; 32:723–735. https://doi.org/10.1681/ASN.2020050598 PMID: 39547218

38. Flejge J. Phosphate binders in chronic kidney disease: an updated narrative review of recent data. J Nephrol. 2020 Jun; 33:497–508. https://doi.org/10.1007/s40620-019-00689-w PMID: 31865606

39. Tatami Y, Yasuda Y, Suzuki S, Ishii H, Sawai A, Shibata Y, et al. Impact of abdominal aortic calcification on long-term cardiovascular outcomes in patients with chronic kidney disease. Atherosclerosis. 2015; 243: 349–55 https://doi.org/10.1016/j.atherosclerosis.2015.01.016 PMID: 26519631

40. Chang JR, Sun N, Liu Y, et al. Erythropoietin attenuates vascular calcification by inhibiting endoplasmic reticulum stress in rats with chronic kidney disease. Peptides. 2020 Jan; 123:170181. https://doi.org/10.1016/j.peptides.2019.12.008 PMID: 31689455

41. Li X, Jiang X, He F, et al. Effect of erythropoietin on calcification of vascular smooth muscle cells and Its Molecular Regulatory Mechanism. J Cardiovasc Transl Res. 2020 Nov 10. https://doi.org/10.1007/s12265-020-10081-w PMID: 33170424

42. Mokas S, Larivière R, Lamalice L, et al. Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification. Kidney Int. 2016 Sep; 90:598–609. https://doi.org/10.1016/j.kint.2016.05.020 PMID: 27470678

43. Mikolasevic I, Milic S, Stimac D, Zaputovic L, Lukenda Zanko V, Gulin T, et al. Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis? Eur J Intern Med. 2016; 30:39–103. https://doi.org/10.1016/j.ejim.2016.01.026 PMID: 26905320
44. Nakashima A, Ohkido I, Yokoyama K, Mafune A, Urashima M, Yokoo T. Proton pump inhibitor use and magnesium concentrations in hemodialysis patients: a cross-sectional study. PLoS One. 2015; 10: e0143656. https://doi.org/10.1371/journal.pone.0143656 PMID: 26618538

45. Ter Braake AD, Shanahan CM, de Baaij JHF. Magnesium counteracts vascular calcification: passive interference or active modulation? Arterioscler Thromb Vasc Biol. 2017; 37(8):1431–1435. https://doi.org/10.1161/ATVBAHA.117.309182 PMID: 28663256

46. Ter Braake AD, Tinnemans PT, Shanahan CM, Hoenderop JGJ, de Baaij JHF. Magnesium prevents vascular calcification in vitro by inhibition of hydroxyapatite crystal formation. Sci Rep. 2018; 8(1):2069. https://doi.org/10.1038/s41598-018-20241-3 PMID: 29391410

47. London GM, Gue´rin AP, Marchais SJ, M´etivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18:1731–1740. https://doi.org/10.1093/ndt/gfg414 PMID: 12937218

48. Hörl WH. Comparing the efficacy of intravenous iron and oral iron in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3:1599–1605. https://doi.org/10.2215/CJN.02120508 PMID: 18815240